Evaluation and treatment of the patient coinfected with hepatitis B and HIV

Ellen Kitchell; Mamta K. Jain

doi:10.1007/s11904-008-0017-1

Evaluation and treatment of the patient coinfected with hepatitis B and HIV

Ellen Kitchell, Mamta K. Jain

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

Original language	English (US)
Pages (from-to)	103-111
Number of pages	9
Journal	Current HIV/AIDS Reports
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s11904-008-0017-1
State	Published - Aug 2008

ASJC Scopus subject areas

Virology
Infectious Diseases

Access to Document

10.1007/s11904-008-0017-1

Cite this

@article{ae9900c9c956419faaebd8a1aae18b05,

title = "Evaluation and treatment of the patient coinfected with hepatitis B and HIV",

abstract = "Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.",

author = "Ellen Kitchell and Jain, {Mamta K.}",

note = "Funding Information: Dr. Kitchell has no potential conflict of interest relevant to this article. Dr. Jain has received research grant support from Gilead Sciences and Vertex Pharmaceuticals.",

year = "2008",

month = aug,

doi = "10.1007/s11904-008-0017-1",

language = "English (US)",

volume = "5",

pages = "103--111",

journal = "Current HIV/AIDS Reports",

issn = "1548-3568",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Evaluation and treatment of the patient coinfected with hepatitis B and HIV

AU - Kitchell, Ellen

AU - Jain, Mamta K.

N1 - Funding Information: Dr. Kitchell has no potential conflict of interest relevant to this article. Dr. Jain has received research grant support from Gilead Sciences and Vertex Pharmaceuticals.

PY - 2008/8

Y1 - 2008/8

N2 - Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

AB - Hepatitis B virus (HBV) is a common coinfection in HIV-infected patients, and significant liver disease and mortality occur as the result of this disease combination. Potent anti-HBV therapy is available and can be used to improve outcomes by suppressing HBV DNA. Many HBV agents have dual activity with HIV and may be used to treat both diseases. However, care must be taken when using HBV nucleos(t)ides that have not been fully studied in the HIV-infected population because the emergence of strains resistant to HIV treatment has been reported. Careful monitoring of response to treatment is needed when treating an HIV/HBV patient with severe immune suppression. Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population.

UR - http://www.scopus.com/inward/record.url?scp=48949102249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48949102249&partnerID=8YFLogxK

U2 - 10.1007/s11904-008-0017-1

DO - 10.1007/s11904-008-0017-1

M3 - Article

C2 - 18627658

AN - SCOPUS:48949102249

SN - 1548-3568

VL - 5

SP - 103

EP - 111

JO - Current HIV/AIDS Reports

JF - Current HIV/AIDS Reports

IS - 3

ER -

Evaluation and treatment of the patient coinfected with hepatitis B and HIV

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this